Concepedia

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

Kevin Hollevoet, Kristiaan Nackaerts, Robert C. Gosselin, Walter De Wever, Lionel Bosquée, Paul De Vuyst, Paul Germonpré, Eliane Kellen, Catherine Legrand, Yoshiro Kishi,

Journal of Thoracic Oncology · 2011 · 83 citations · 32 references

DOIFull text

Open access

Concepts

References

32

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

, , +13

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

, , +9

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold et al. · Journal of Clinical Oncology · 2005 · 621 citations · Full text

, , +14